Form 4 for NVCR NovoCure Ltd

Accepted 2023-03-02 00:00:00 ET · period of report 2023-02-28 · accession 0001645113-23-000030 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2023-03-02	2023-02-28	NVCR	Shah Pritesh	Chief Growth Off	A - Grant	$0.00	+19.1K	101.9K	+23%	$0
D	2023-03-02	2023-03-01	NVCR	Shah Pritesh	Chief Growth Off	S - Sale	$76.36	-1,923	100.0K	-2%	-$146.8K
D	2023-03-02	2023-02-28	NVCR	Shah Pritesh	Chief Growth Off	A - Grant	$76.97	+31.7K	31.7K	New	+$2.44M

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Ordinary Shares	2023-02-28	A	A	19,055	$0.00	101,898	D	—	—	(F1) Represents restricted share units that are scheduled to vest in equal installments on each of February 28, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates.
2	Common	Ordinary Shares	2023-03-01	S	D	1,923	$76.36	99,975	D	—	—	(F2) Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
3	Derivative	Options to Buy Ordinary Shares	2023-02-28	A	A	31,691	$76.97	31,691	D	$76.97 · 2024-02-28 to 2033-02-27	31,691 Ordinary Shares	(F3) Options to buy 31,691 ordinary shares will vest and become exercisable in equal installments on each of February 28, 2024, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates.